Cargando…

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study

OBJECTIVES: To complement Sustainable Development Goal (SDG) indicator 3.b.3 that monitors access to medicines for all, a corresponding child-specific methodology was developed tailored to the health needs of children. This methodology could aid countries in monitoring accessibility to paediatric me...

Descripción completa

Detalles Bibliográficos
Autores principales: Joosse, Iris R, Mantel-Teeuwisse, Aukje K, Suleman, Fatima, van den Ham, Hendrika A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106062/
https://www.ncbi.nlm.nih.gov/pubmed/37041064
http://dx.doi.org/10.1136/bmjopen-2022-065929
_version_ 1785026342967836672
author Joosse, Iris R
Mantel-Teeuwisse, Aukje K
Suleman, Fatima
van den Ham, Hendrika A
author_facet Joosse, Iris R
Mantel-Teeuwisse, Aukje K
Suleman, Fatima
van den Ham, Hendrika A
author_sort Joosse, Iris R
collection PubMed
description OBJECTIVES: To complement Sustainable Development Goal (SDG) indicator 3.b.3 that monitors access to medicines for all, a corresponding child-specific methodology was developed tailored to the health needs of children. This methodology could aid countries in monitoring accessibility to paediatric medicines in a validated manner and on a longitudinal basis. We aimed to provide proof of concept of this adapted methodology by applying the method to historical datasets. METHOD: A core set of child-appropriate medicines was selected for two groups of children: children aged 1–59 months and children aged 5–12 years. To enable calculation of affordability of medicines for children, the number of units needed for treatment was created, incorporating the recommended dosage and duration of treatment for the specific age group. The adapted methodology was applied to health facility survey data from Burundi (2013), China (2012) and Haiti (2011) for one age group. SDG indicator 3.b.3 scores and (mean) individual facility scores were calculated per country and sector. RESULTS: We were able to calculate SDG indicator 3.b.3 based on historical data from Burundi, China and Haiti with the adapted methodology. In this case study, all individual facilities failed to reach the 80% benchmark of accessible medicines, resulting in SDG indicator 3.b.3 scores of 0% for all 3 countries. Mean facility scores ranged from 22.2% in Haiti to 40.3% in Burundi for lowest-price generic medicines. Mean facility scores for originator brands were 0%, 16.5% and 9.9% for Burundi, China and Haiti, respectively. The low scores seemed to stem from the low availability of medicines. CONCLUSION: The child-specific methodology was successfully applied to historical data from Burundi, China and Haiti, providing proof of concept of this methodology. The proposed validation steps and sensitivity analyses will help determine its robustness and could lead to further improvements.
format Online
Article
Text
id pubmed-10106062
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101060622023-04-17 Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study Joosse, Iris R Mantel-Teeuwisse, Aukje K Suleman, Fatima van den Ham, Hendrika A BMJ Open Health Services Research OBJECTIVES: To complement Sustainable Development Goal (SDG) indicator 3.b.3 that monitors access to medicines for all, a corresponding child-specific methodology was developed tailored to the health needs of children. This methodology could aid countries in monitoring accessibility to paediatric medicines in a validated manner and on a longitudinal basis. We aimed to provide proof of concept of this adapted methodology by applying the method to historical datasets. METHOD: A core set of child-appropriate medicines was selected for two groups of children: children aged 1–59 months and children aged 5–12 years. To enable calculation of affordability of medicines for children, the number of units needed for treatment was created, incorporating the recommended dosage and duration of treatment for the specific age group. The adapted methodology was applied to health facility survey data from Burundi (2013), China (2012) and Haiti (2011) for one age group. SDG indicator 3.b.3 scores and (mean) individual facility scores were calculated per country and sector. RESULTS: We were able to calculate SDG indicator 3.b.3 based on historical data from Burundi, China and Haiti with the adapted methodology. In this case study, all individual facilities failed to reach the 80% benchmark of accessible medicines, resulting in SDG indicator 3.b.3 scores of 0% for all 3 countries. Mean facility scores ranged from 22.2% in Haiti to 40.3% in Burundi for lowest-price generic medicines. Mean facility scores for originator brands were 0%, 16.5% and 9.9% for Burundi, China and Haiti, respectively. The low scores seemed to stem from the low availability of medicines. CONCLUSION: The child-specific methodology was successfully applied to historical data from Burundi, China and Haiti, providing proof of concept of this methodology. The proposed validation steps and sensitivity analyses will help determine its robustness and could lead to further improvements. BMJ Publishing Group 2023-04-11 /pmc/articles/PMC10106062/ /pubmed/37041064 http://dx.doi.org/10.1136/bmjopen-2022-065929 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Services Research
Joosse, Iris R
Mantel-Teeuwisse, Aukje K
Suleman, Fatima
van den Ham, Hendrika A
Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
title Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
title_full Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
title_fullStr Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
title_full_unstemmed Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
title_short Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
title_sort sustainable development goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106062/
https://www.ncbi.nlm.nih.gov/pubmed/37041064
http://dx.doi.org/10.1136/bmjopen-2022-065929
work_keys_str_mv AT joosseirisr sustainabledevelopmentgoalindicatorformeasuringavailabilityandaffordabilityofmedicinesforchildrenaproofofconceptstudy
AT mantelteeuwisseaukjek sustainabledevelopmentgoalindicatorformeasuringavailabilityandaffordabilityofmedicinesforchildrenaproofofconceptstudy
AT sulemanfatima sustainabledevelopmentgoalindicatorformeasuringavailabilityandaffordabilityofmedicinesforchildrenaproofofconceptstudy
AT vandenhamhendrikaa sustainabledevelopmentgoalindicatorformeasuringavailabilityandaffordabilityofmedicinesforchildrenaproofofconceptstudy